Recombinant Human Anti-HCV E2 Antibody (HEPC74) (CAT#: HPAB-0196CQ)

Figure 1 Controls for sE2 binding to CD81−CHO or SR-B1−CHO cells.

ELISA binding of HEPC74 and HEPC98 to strain 1a154 sE2.

Mankowski, M. C., Kinchen, V. J., Wasilewski, L. N., Flyak, A. I., Ray, S. C., Crowe, J. E., & Bailey, J. R. (2018). Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proceedings of the National Academy of Sciences, 115(1), E82-E91.

Figure 2 HEPC74/HEPC98 neutralization follows Bliss independence.

Median effect plots comparing experimental inhibition (blue) to the inhibition predicted by either the Loewe additivity (red) or Bliss independence (orange) models. Statistically significant differences between the experimental inhibition and Loewe or Bliss predictions are indicated with red and orange asterisks, respectively. Experimental neutralization values are the means of duplicate measurements. Loewe and Bliss values are the means of four individual predictions made at each antibody concentration using data from individual NAb neutralization.

Mankowski, M. C., Kinchen, V. J., Wasilewski, L. N., Flyak, A. I., Ray, S. C., Crowe, J. E., & Bailey, J. R. (2018). Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proceedings of the National Academy of Sciences, 115(1), E82-E91.

Figure 3 HEPC74 and HEPC98 have distinct mechanisms of neutralization.

ELISA binding of HEPC74 or HEPC98 to strain 1a154 E1E2 alone, or in the presence serial dilutions of nonspecific human IgG, HEPC74, or HEPC98.

Mankowski, M. C., Kinchen, V. J., Wasilewski, L. N., Flyak, A. I., Ray, S. C., Crowe, J. E., & Bailey, J. R. (2018). Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proceedings of the National Academy of Sciences, 115(1), E82-E91.

Figure 1 Recombinant Human Anti-HCV E2 Antibody (HEPC74) (HPAB-0196CQ) in SDS-PAGE

SDS-PAGE analysis of HPAB-0196CQ in non-reduced (Lane 2) and reduced (Lane 1) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.

Figure 2 Recombinant Human Anti-HCV E2 Antibody (HEPC74) (HPAB-0196CQ) in SEC-HPLC

SEC-HPLC analysis of HPAB-0196CQ shows that the purity is more than 95%

Figure 3 Recombinant Human Anti-HCV E2 Antibody (HEPC74) (HPAB-0196CQ) in WB

Western blot analysis of HPAB-0196CQ was performed with Hepatitis C virus (HCV-1a) E2 Protein (His Tag).
Lane 1: Reducing antigen (0.1 μg)
Lane 2: Reducing antigen (0.3 μg)
Lane 3: Reducing antigen (0.6 μg)
The secondary antibody: HRP Goat Anti-Human IgG (H+L)

Figure 4 Recombinant Human Anti-HCV E2 Antibody (HEPC74) (HPAB-0196CQ) in ELISA

ELISA analysis of HPAB-0196CQ was performed by coating with Hepatitis C virus (HCV-1a) E2 Protein (His Tag).
The secondary antibody: HRP Goat Anti-Human IgG (H+L)

Figure 5 Recombinant Human Anti-HCV E2 Antibody (HEPC74) (HPAB-0196CQ) in Dot Blot

Dot Blot analysis of HPAB-0196CQ was performed with Hepatitis C virus (HCV-1a) E2 Protein (His Tag).
The secondary antibody: HRP Goat Anti-Human IgG (H+L)